Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Current Deferred Revenue (2023 - 2025)

Historic Current Deferred Revenue for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $2.7 million.

  • Tonix Pharmaceuticals Holding's Current Deferred Revenue changed N/A to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year change of. This contributed to the annual value of $1.8 million for FY2024, which is 3906.04% down from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Current Deferred Revenue of $2.7 million as of Q3 2025.
  • Tonix Pharmaceuticals Holding's 5-year Current Deferred Revenue high stood at $3.0 million for Q2 2025, and its period low was $1.8 million during Q4 2024.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median Current Deferred Revenue value was $2.7 million (recorded in 2025), while the average stood at $2.5 million.
  • Data for Tonix Pharmaceuticals Holding's Current Deferred Revenue shows a peak YoY increase of 3906.04% (in 2024) and a maximum YoY decrease of 3906.04% (in 2024) over the last 5 years.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Current Deferred Revenue (Quarter) stood at $3.0 million in 2023, then plummeted by 39.06% to $1.8 million in 2024, then soared by 47.03% to $2.7 million in 2025.
  • Its Current Deferred Revenue stands at $2.7 million for Q3 2025, versus $3.0 million for Q2 2025 and $1.9 million for Q1 2025.